<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647072</url>
  </required_header>
  <id_info>
    <org_study_id>eman elberry</org_study_id>
    <nct_id>NCT03647072</nct_id>
  </id_info>
  <brief_title>PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy</brief_title>
  <official_title>Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton
      Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in
      patients with Non-hodgkin Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton
      Pump Inhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in
      patients with Non-hodgkin Lymphoma to compare the difference in efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients eith radiological and clinical improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients eith radiological and clinical improvement after cycles of chemotherapy</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHOP only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP Plus Lanzoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHOP Plus Lanzoprazole 60 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP Plus Famotidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHOP Plus Famotidine 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP</intervention_name>
    <description>CHOP only</description>
    <arm_group_label>CHOP</arm_group_label>
    <other_name>CHOP protocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP Plus Lanzoprazole</intervention_name>
    <description>CHOP plus Lanzoprazole 60 mg</description>
    <arm_group_label>CHOP Plus Lanzoprazole</arm_group_label>
    <other_name>CHOP Plus Lanzoprazole 60</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP Plus Famotidine</intervention_name>
    <description>CHOP Plus Famotidine 40 mg</description>
    <arm_group_label>CHOP Plus Famotidine</arm_group_label>
    <other_name>CHOP Plus Famotidine 40</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DLBCL Lymphoma subtype --No comorbid disease

        Exclusion Criteria:

          -  Pregnancy

          -  Peptic ulcer

          -  Severe cardiac disease

          -  Osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahar K Hegazy, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical pharmacy Department- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sahar M El-Haggar, prof</last_name>
    <role>Study Director</role>
    <affiliation>Clinical pharmacy Department- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzan A Alhassanin, Ph D</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Oncology Department-Menoufia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman I A El berri, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical pharmacy Department-Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <phone>00201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>PhDTropical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

